Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review

  • Girard M
  • Osmanov S
  • Assossou O
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

The development of a safe, effective and globally affordable HIV vaccine offers the best hope for the future control of the HIV-1 pandemic. Since 1987, scores of candidate HIV-1 vaccines have been developed which elicited varying degrees of protective responses in nonhuman primate models, including DNA vaccines, subunit vaccines, live vectored recombinant vaccines and various prime-boost combinations. Four of these candidate vaccines have been tested for efficacy in human volunteers, but, to the exception of the recent RV144 Phase III trial in Thailand, which elicited a modest but statistically significant level of protection against infection, none has shown efficacy in preventing HIV-1 infection or in controlling virus replication and delaying progression of disease in humans. Protection against infection was observed in the RV144 trial, but intensive research is needed to try to understand the protective immune mechanisms at stake. Building-up on the results of the RV144 trial and deciphering what possibly are the immune correlates of protection are the top research priorities of the moment, which will certainly accelerate the development of an highly effective vaccine that could be used in conjunction with other HIV prevention and treatment strategies. This article reviews the state of the art of HIV vaccine development and discusses the formidable scientific challenges met in this endeavor, in the context of a better understanding of the immunopathogenesis of the disease. © 2011 Elsevier Ltd.

Author-supplied keywords

  • AIDS
  • AIDS Vaccines
  • Animal models
  • CD4 antigen
  • CD4+ T lymphocyte
  • CD8 antigen
  • CD8+ T lymphocyte
  • Clinical Trials as Topic
  • DNA vaccine
  • HIV Infections
  • HIV-1
  • Human immunodeficiency virus 1
  • Human immunodeficiency virus 1 infection
  • Human immunodeficiency virus vaccine
  • Humans
  • Immune responses
  • Innate immunity
  • Lentiviruses
  • Nef protein
  • Pathogenesis
  • Vaccines
  • Vaccines, Attenuated
  • Vaccines, DNA
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • cellular immunity
  • disease course
  • drug efficacy
  • glycoprotein gp 120
  • glycoprotein gp 41
  • highly active antiretroviral therapy
  • human
  • immunization
  • immunopathogenesis
  • inactivated vaccine
  • innate immunity
  • lipopeptide
  • live vaccine
  • mucosal immunity
  • neutralizing antibody
  • nonhuman
  • priority journal
  • recombinant vaccine
  • review
  • sexual intercourse
  • sexual transmission
  • transactivator protein
  • virion
  • virus envelope protein
  • virus like agent
  • virus load
  • virus replication
  • virus transmission

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Authors

  • M P Girard

  • S Osmanov

  • O M Assossou

  • M.-P. Kieny

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free